You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Success prnasia
January 31, 2018
WuXi Biologics today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-50
WuXi Biologics Announces Formation of Scientific Advisory Board prnasia
January 25, 2018
Internationally Renowned Scientists and Entrepreneurs to Provide Guidance and Insights to Further Advance the Company's Leading Position in Developing Enabling Technologies for Biologics Discovery, Development and Manufacturing
WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory prnasia
November 03, 2017
An opening ceremony for the WuXi Biologics and Pall joint laboratory was held by the two parties on November 2, 2017.
Ligand to receive US$2mn from WuXi Biologics for licensing antibody pharmaasia
August 23, 2017
Ligand is also entitled to future milestones and royalties from this antibody.
WuXi Biologics is Officially Listed on the Hong Kong, S.A.R., China Stock Exchange en-cphi.cn
June 14, 2017
On June 13, 2017, WuXi Biologics (Cayman) Inc. ("the Company"; stock code: 2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange of Hong Kong, S.A.R., China.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page